Europe PromarkerD patent granted for diabetic kidney disease
Filed with ASX · · 1 page · English
Proteomics International Laboratories Ltd. on 6ix
Story so far
Earlier from Proteomics International Laboratories
- Underwriters take final $342,000 of Proteomics Options
- Conversion of 90% of Proteomics Options raises of $3m
- Directors Exercise PIQ Options
- Proteomics secures underwriting - PIQ Options to raise $3.4m
- Proteomics launches PromarkerD
Later from Proteomics International Laboratories
- Appendix 4C - March 2018 Quarterly Report
- Proteomics signs deal to launch PromarkerD test in US market
- Proteomics signs deal with Patia for PromarkerD in Mexico
- Further information on new licence deals in USA and Mexico
- Proteomics secures major contract - nears cash flow positive
Follow Proteomics International Laboratories into a list and get an email when it puts out news.
Follow Proteomics International Laboratories